References
- Zinzani P L, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, Guardiani L, Mazza P, Marra R, Ronconi F, Lauta V M, Bendandi M, Gherlinzoni F, Gentilini P, Ciccone F, Cellini C, Stefoni V, Ricciuti F, Gobbi M, Tura S. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. Journal of Clinical Oncology 2000; 18: 773–779
- Solal-Celigny P, Brice P, Brousse N, Caspard H, Bastion Y, Haioun C, Bosly A, Tilly H, Bordessoule D, Sebban C, Harousseau J L, Morel P, Dupas B, Plassart F, Vasile N, Fort N, Leporrier M. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Group d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology 1996; 14: 514–519
- Zinzani P L, Pulsoni A, Pernotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta V M, Guardigli L, Gentilini P, Tucci A, Molinari A L, Gobbi M, Falini B, Fattori P P, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. Journal of Clinical Oncology 2004; 22: 2654–2661
- Zinzani P L, Bendandi M, Magagnoli M, Gherlinzoni F, Merla E, Tura S. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Annals of Oncology 1997; 8: 379–383
- Boogaerts M A, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani P L, Binet J L, Feremans W, Marcus R, Bosch F, Verhoef G, Klein M. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology 2001; 19: 4252–4258
- Rossi J F, Van Hoof A, de Boeck K, Johnson S A, Bron D, Foussard C, Lister T A, Berthou C, Kramer M H, Littlewood T J, Marcus R E, Deconinck E, Montillo M, Guibon O, Tollerfield S M. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 2004; 22: 1260–1267
- Carbone P P, Kaplan H S, Musshoff K, Smithers D W, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Research 1971; 31: 1860–1861
- Harris N, Jaffe E, Stein H, Banks P M, Chan J K, Cleary M L, Delsol G, De Wolf-Peeters C, Falini B, Gatter K C. A revised European-American classification of lymphoid neoplasms: a proposal from the International Study Group. Blood 1994; 84: 1361–1392
- Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, Lister T A, Vose J M, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris N L, Armitage J O, Carter W, Hoppe R, Canellos G P. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology 1999; 17: 1244–1253, NCI Sponsored International Working Group
- Klasa R J, Meyer R M, Shustik C, Sawka C A, Smith A, Guevin R, Maksymiuk A, Rubinger M, Samosh M, Laplante S, Grenier J F. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. Journal of Clinical Oncology 2002; 20: 4649–4654
- Hochster H S, Oken M M, Winter J N, Gordon L I, Raphael B G, Bennett J M, Cassileth P A. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up – a report from the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2000; 18: 987–994
- Santini G, Nati S, Spriano M, Gallamini A, Pierluigi D, Congiu A M, Truini M, Rubagotti A, Chisesi T, Vimercati R, Rossi E, Sertoli M R, Mattei D, Marino G, Gobbi M. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 282–286